Assignee
GLAXOSMITHKLINE INTELLECTUAL PROPERTY MAN LIMITED
GB·8 granted patents·3 pending applications·10 citations·filing 2015–2025
Top patents by PatentIndex Score
11 records- 0184US11180569B2Methods of treating autoimmune disorders using a combination of anti-CD20 and anti-blys antibodiesGLAXOSMITHKLINE INTELLECTUAL PROPERTY MAN LIMITED·Filed 2016·Granted Nov 23, 2021·2 cites·14 claims
- 0279US2024360237A1Dosing Regimen of Combination of Anti-CD20 and Anti-BLyS AntibodiesGLAXOSMITHKLINE INTELLECTUAL PROPERTY MAN LIMITED·Filed 2024·Application pending·0 cites
- 0376US10556009B2Anti-Blys antibody formulations and methods of treatment using themGLAXOSMITHKLINE INTELLECTUAL PROPERTY MAN LIMITED·Filed 2015·Granted Feb 11, 2020·2 cites·25 claims
- 0473US12060431B2Dosing regimen of combination of ANTICD20 and anti-BlyS antibodiesGLAXOSMITHKLINE INTELLECTUAL PROPERTY MAN LIMITED·Filed 2021·Granted Aug 13, 2024·0 cites·10 claims
- 0572US2025249095A1High Concentratioin Anti-BLYS Pharmaceutical FormulationsGLAXOSMITHKLINE INTELLECTUAL PROPERTY MAN LIMITED·Filed 2025·Application pending·0 cites
- 0671US12296007B2High concentration anti-blys pharmaceutical formulationsGLAXOSMITHKLINE INTELLECTUAL PROPERTY MAN LIMITED·Filed 2021·Granted May 13, 2025·0 cites·16 claims
- 0764US11179463B2BLyS antibody formulationGLAXOSMITHKLINE INTELLECTUAL PROPERTY MAN LIMITED·Filed 2020·Granted Nov 23, 2021·0 cites·14 claims
- 0854USD868244SHousing for an auto injectorGLAXOSMITHKLINE INTELLECTUAL PROPERTY MAN LIMITED·Filed 2017·Granted Nov 26, 2019·5 cites·1 claims
- 0954US2018289804A1Antibody formulationGLAXOSMITHKLINE INTELLECTUAL PROPERTY MAN LIMITED·Filed 2018·Application pending·0 cites
- 1037USD981557SHousing for an autoinjectorGLAXOSMITHKLINE INTELLECTUAL PROPERTY MAN LIMITED·Filed 2019·Granted Mar 21, 2023·1 cites·1 claims
- 1132US11247807B2Healthcare product packageGLAXOSMITHKLINE INTELLECTUAL PROPERTY MAN LIMITED·Filed 2017·Granted Feb 15, 2022·0 cites·26 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →